Metraipolis › archive › dc_a0df94df2ef9

Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target — Europe PMC PMID:42193138

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42193138
DOI
10.3390/cimb48050535
License (as archived)
solo-consultazione
Archived
2026-11-01T14:08:36.909Z
SHA-256 of the archived text
f6385145ca976cd004a290faedb53bde1e011461d665e970b3469a69e7db2ea1
Stable URL of this page
https://metraipolis.com/documento/dc_a0df94df2ef9

How to cite

Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target — Europe PMC PMID:42193138 — Europe PMC (en), https://europepmc.org/article/MED/42193138 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a0df94df2ef9 (Metraipolis archive dc_a0df94df2ef9, sha256 f6385145ca976cd004a290faedb53bde1e011461d665e970b3469a69e7db2ea1)
BibTeX
@misc{dca0df94df2ef9,
  title = {Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target — Europe PMC PMID:42193138},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42193138},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a0df94df2ef9; sha256 f6385145ca976cd004a290faedb53bde1e011461d665e970b3469a69e7db2ea1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42193138. Agents can read the archived copy with the MCP tool read_document.